Regulation of STEP61 and tyrosine-phosphorylation of NMDA and AMPA receptors during homeostatic synaptic plasticity
Sustained changes in network activity cause homeostatic synaptic plasticity in part by altering the postsynaptic accumulation of N-methyl-D-aspartate receptors (NMDAR) and α-amino-3-hydroxyle-5-methyl-4-isoxazolepropionic acid receptors (AMPAR), which are primary mediators of excitatory synaptic transmission. A key trafficking modulator of NMDAR and AMPAR is STriatal-Enriched protein tyrosine Phosphatase (STEP61) that opposes synaptic strengthening through dephosphorylation of NMDAR subunit GluN2B and AMPAR subunit GluA2. However, the role of STEP61 in homeostatic synaptic plasticity is unknown.
We demonstrate here that prolonged activity blockade leads to synaptic scaling, and a concurrent decrease in STEP61 level and activity in rat dissociated hippocampal cultured neurons. Consistent with STEP61 reduction, prolonged activity blockade enhances the tyrosine phosphorylation of GluN2B and GluA2 whereas increasing STEP61 activity blocks this regulation and synaptic scaling. Conversely, prolonged activity enhancement increases STEP61 level and activity, and reduces the tyrosine phosphorylation and level of GluN2B as well as GluA2 expression in a STEP61–dependent manner.
Given that STEP61-mediated dephosphorylation of GluN2B and GluA2 leads to their internalization, our results collectively suggest that activity-dependent regulation of STEP61 and its substrates GluN2B and GluA2 may contribute to homeostatic stabilization of excitatory synapses.
KeywordsSTEP GluN2B GluA2 Tyrosine phosphorylation Tetrodotoxin Bicuculline Hippocampal neurons Homeostatic plasticity Synaptic scaling
STriatal-Enriched protein tyrosine Phosphatase
α-amino-3-hydroxyle-5-methyl-4-isoxazolepropionic acid receptor
Protein kinase A
miniature excitatory postsynaptic current
real-time quantitative polymerase chain reaction
In response to sustained changes in neuronal activity, homeostatic synaptic plasticity maintains synaptic strength and flexibility within physiological limit. This plasticity is expressed in part by dynamic changes in the postsynaptic levels of NMDARs and AMPARs that mediate excitatory synaptic transmission . A key trafficking modulator of both NMDAR and AMPAR is STEP61, a protein tyrosine (Tyr) phosphatase in the central nervous system that has two main alternatively spliced forms, the cytosolic STEP46 and the membrane-associated STEP61 . Tightly associated with the postsynaptic density, STEP61 regulates the Tyr phosphorylation and surface density of NMDARs and AMPARs [3, 4, 5, 6]. This regulation contributes to Hebbian long-term potentiation [4, 7] and several neuropsychiatric disorders most notably Alzheimer’s disease  and Fragile X-syndrome .
We have previously identified mRNA transcripts whose expressions are regulated by prolonged activity perturbation  due to a critical role of transcription in homeostatic synaptic plasticity [9, 10]. Of these activity-regulated transcripts, we identified PTPN5 that encodes STEP . The present study investigated whether STEP61 contributes to homeostatic synaptic plasticity.
Results and discussion
Prolonged alterations of hippocampal network activity regulate STEP61 level and activity
Prolonged alterations of hippocampal network activity regulate Tyr-phosphorylation of GluN2B and GluA2 in a STEP61-dependent manner
Consistent with the TTX-induced decrease in STEP61 level and activity (Fig. 2b, d), prolonged TTX treatment increased the levels of Tyr1472-phosphorylated GluN2B (GluN2B-pY1472) and 3Tyr-phopshorylated GluA2 (GluA2-p3Y) compared to CTL treatment without affecting their total protein expression (Fig. 3a–c). In contrast, BC treatment for 24–48 h decreased the levels of GluN2B-pY1472 and GluA2-p3Y (Fig. 3d–f), concurrently with an increase in STEP61 level and activity (Fig. 2c, d). Interestingly, total levels of GluN2B and GluA2 were reduced by 48 h BC application (Fig. 3d, e).
In TAT-STEP C/S, a C300S point mutation inactivates STEP46, allowing it to bind constitutively to substrates but not to dephosphorylate them [13, 15, 16]. Consistently, introduction of TAT-STEP C/S in CTL-treated neurons significantly increased the levels of GluN2B-pY1472 and GluA2-p3Y compared to TAT-myc application (Fig. 4d, e, Additional file 1: Figure S1D). Preincubation with TAT-STEP C/S but not TAT-myc blocked the BC-induced reduction in the levels of GluN2B-pY1472, total GluN2B, and total GluA2 but not GluA2-p3Y (Fig. 4d, e). Since specific Tyr residues regulated by STEP61 remain unknown, our analyses for GluA2-p3Y may not have revealed the effect of TAT-STEP C/S if STEP61 causes dephosphorylation of only one Tyr. Nonetheless, these results suggest that STEP61 mediates the BC-induced changes in Tyr1472-phosphorylation of GluN2B and abundance of GluN2B and GluA2.
Enhancement of STEP activity blocks synaptic scaling
Interestingly, prolonged activity enhancement increased STEP61 (Fig. 1g, Fig. 2c) and decreased Tyr-phosphorylation of GluN2B and GluA2 (Fig. 3d–f, Fig. 4d, e) without inducing synaptic down-scaling (Fig. 1a–d), suggesting that this STEP61 upregulation may cause internalization of extrasynaptic GluN2B and GluA2. Indeed, activity-dependent AMPAR endocytosis requires GluA2  and occurs extrasynaptically . Similarly, GluN2B-containing NMDARs enriched in extrasynaptic sites  undergo robust endocytosis [17, 18]. The BC-induced STEP61-dependent decrease in GluA2 and GluN2B abundance (Fig. 3d, e, Fig. 4d, e) may provide an additional homeostatic defense to limit membrane depolarization and overstimulation of extrasynaptic GluN2B-containing NMDARs, which is shown to cause excitotoxicity .
It remains unknown how prolonged activity perturbation regulates STEP61. Previous studies have reported that Ser221 of STEP61 is dephosphorylated by calcium-dependent calcineurin upon NMDAR activation  and phosphorylated by protein kinase A (PKA) upon stimulation of dopamine D1 receptor . Interestingly, synaptic scaling is shown to involve reduced calcium influx to the postsynaptic neuron , reduced calcineurin activity , and enhanced PKA activity at excitatory synapses . Hence, prolonged activity blockade could increase Ser221-phosphorylation of STEP61 (Fig. 2b, d) by reduced calcineurin activity and/or enhanced PKA activity, in addition to decreasing STEP61 level by transcriptional down-regulation (Fig. 1e, f). Considering that a loss of PKA from synapses was found during synaptic downscaling , reduced PKA activity may contribute to the BC-induced decrease in Ser221-phosphorylation of STEP61 (Fig. 2c, d).
In summary, we demonstrate a bidirectional modulation of STEP61 level and activity by prolonged alterations of hippocampal network activity, resulting in correlative changes in Tyr-phosphorylation of STEP61 substrates, GluN2B and GluA2. We also show that the reduction in STEP61 contributes to synaptic scaling. Future studies should test if this regulation alters NMDAR and AMPAR surface density during homeostatic plasticity (Fig. 5e). Investigating how prolonged activity perturbation regulates STEP61 should provide mechanistic insights into the dysregulation of STEP61 expression, which are present in multiple neuropathologies .
Materials and methods
Hippocampal neuronal culture
The Institutional Animal Care and Use Committee at the University of Illinois Urbana-Champaign approved all experimental procedures involving animals. Primary dissociated hippocampal cultures were prepared from Sprague–Dawley rat embryos at embryonic day 18 and plated at high density (330 cells/mm2) as described . At 10–13 days in vitro, neurons were treated for 24–48 h with vehicle control (0.1 % dH2O), TTX (1 μM), and BC (20 μM) (all Tocris).
Whole-cell patch-clamp recordings of mEPSCs (>150 events per neuron) were performed at 23–25 °C from pyramidal neurons held at −60 mV in external solution containing 1 μM TTX and 20 μM BC as described [12, 25] using a Multiclamp 700B amplifier, Digidata1440A, and the pClamp 10.2 (Molecular Devices). Signals were acquired 3 min after making the whole-cell configuration, filtered at 1 kHz, and sampled at 10 kHz on gap free mode (5 min). The mEPSCs were detected with a 10 pA thresholds and analyzed by Mini Analysis (Synaptosoft).
The QPCR was performed with the StepOnePlus real-time PCR system (Applied Biosystems) using total RNA (1–2 μg) as described . The forward and reverse primer sequences for PTPN5 were 5’-GGAGTCAGCCCATGAATACC-3’ and 5’-CAGACGTACCCTGCTGTGAG-3’ respectively. The primer sequences for GAPDH has been previously described . Following normalization to control GAPDH cDNA levels, the fold change of PTPN5 cDNA levels for each treatment compared to control was determined.
Neuronal lysate samples were prepared in RIPA buffer supplemented with protease inhibitors and Tyr phosphatase inhibitors (1 mM NaVO3, 10 mM Na4O7P2, and 50 mM NaF) as described  and were subjected to immunoblot analysis with primary antibodies against STEP61 (Santa Cruz), STEP61-pS221(), GluN2B and GluA2 (Millipore), GluN2B-pY1472 (PhosphoSolutions), GluA2-p3Y and GAPDH (Cell Signaling). Densitometric quantification following normalization to GAPDH was performed with ImageJ software (National Institutes of Health).
Permeabilized immunostaining were performed with anti-myc antibodies (Thermo-Scientific) as described [12, 25]. Fluorescence images of the neurons were acquired using the same exposure time and analyzed with ImageJ to compare their background-subtracted fluorescence intensities.
Using Origin 9.1 (Origin Lab), the Student’s t test and one-way ANOVA with Tukey’s and Fisher’s multiple comparison tests were performed to identify the statistically significant difference with a priori value (p) < 0.05 between 2 groups and for >3 groups, respectively.
This work is supported by ICR start-up funding from the University of Illinois at Urbana Champaign (HJC), an Epilepsy Foundation Predoctoral Fellowship (SER), and NIH funding MH052711 and MH091037 (PJL).
- 4.Zhang Y, Kurup P, Xu J, Carty N, Fernandez SM, Nygaard HB, et al. Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer’s disease mouse model. Proc Natl Acad Sci U S A. 2010;107(44):19014–9.PubMedCentralCrossRefPubMedGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.